<p>OmniAb, Inc.（NASDAQ:OABI - 獲取免費報告）的股票在週三的午盤交易中上漲了 3.3%。該公司的股票最高交易價格為 1.9250 美元，最後交易價格為 1.90 美元。在午盤交易中，共成交 264,447 股，較平均交易量 547,383 股下降了 52%。該股票此前收盤價為 1.84 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>另外，Weiss Ratings 在 12 月 22 日的研究報告中重申了對 OmniAb 股票的 “賣出（e+）” 評級。三位研究分析師給予該股票買入評級，一位分析師給予賣出評級。根據 MarketBeat.com 的數據，OmniAb 目前的共識評級為 “適度買入”，共識目標價為 6.67 美元。</p>
<p><strong>閲讀我們對 OmniAb 的最新股票分析</strong></p>
<h2>OmniAb 股票表現</h2>
<p>該公司的 50 日簡單移動平均線為 1.80 美元，200 日簡單移動平均線為 1.78 美元。該股票的市值為 2.7352 億美元，市盈率為-3.28，貝塔值為 0.13。</p>
<p>OmniAb（NASDAQ:OABI - 獲取免費報告）最近於 11 月 4 日發佈了季度財報。該公司報告每股收益（EPS）為-0.14 美元，超出市場共識預期的-0.15 美元，超出幅度為 0.01 美元。OmniAb 的股本回報率為-23.14%，淨利潤率為-301.83%。該公司在本季度的收入為 224 萬美元，而分析師預期為 564 萬美元。整體來看，股票研究分析師預測 OmniAb, Inc.在本年度將發佈-0.61 美元的每股收益。</p>
<h2>OmniAb 內部買賣情況</h2>
<p>在其他 OmniAb 新聞中，首席財務官 Kurt A. Gustafson 於 12 月 8 日星期一出售了 23,922 股該公司的股票。股票以平均價格 1.96 美元出售，總交易額為 46,887.12 美元。交易後，首席財務官持有該公司 252,688 股股票，價值約 495,268.48 美元。此交易代表其持股比例下降了 8.65%。該交易已在證券交易委員會的備案中披露，相關文件可通過此鏈接獲取。此外，首席執行官 Matthew W. Foehr 於 12 月 8 日星期一出售了 13,666 股該公司的股票。股票以平均價格 1.96 美元出售，總交易額為 26,785.36 美元。出售後，首席執行官持有該公司 4,360,083 股股票，價值 8,545,762.68 美元。此交易代表其持股比例下降了 0.31%。有關此銷售的更多細節可在官方 SEC 披露中找到。在過去 90 天內，內部人士已出售公司股票 45,632 股，價值 89,439 美元。公司內部人士持有公司股票的 8.60%。</p>
<h2>機構投資者對 OmniAb 的看法</h2>
<p>一些機構投資者最近增加或減少了對該公司的持股。俄亥俄州公共僱員退休系統在第二季度購買了 OmniAb 的新頭寸，價值約 168,000 美元。Connors Investor Services Inc.在第二季度將其在 OmniAb 的持股增加了 25.0%。Connors Investor Services Inc.目前持有 62,000 股該公司的股票，價值 108,000 美元，此前在上個季度又購買了 12,389 股。Towerview LLC 在第二季度將其在 OmniAb 的持股增加了 43.3%。Towerview LLC 目前持有 831,100 股該公司的股票，價值 1,446,000 美元，此前在上個季度又購買了 251,100 股。Private Management Group Inc.在第二季度將其在 OmniAb 的持股增加了 1.1%。Private Management Group Inc.目前持有 2,558,045 股該公司的股票，價值 4,451,000 美元，此前在上個季度又購買了 28,286 股。最後，Isthmus Partners LLC 在第二季度將其在 OmniAb 的持股增加了 21.2%。Isthmus Partners LLC 目前持有 568,043 股該公司的股票，價值 988,000 美元，此前在上個季度又購買了 99,336 股。目前 72.08% 的股票由機構投資者和對沖基金持有。</p>
<h2>OmniAb 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>OmniAb, Inc. NASDAQ: OABI 是一家生物技術公司，專注於治療性抗體的發現和開發。該公司的綜合抗體發現平台結合了專有的轉基因動物模型、體外篩選和計算機工程，以加速候選藥物的識別和優化。OmniAb 提供按服務收費的合作和許可協議，使生物製藥合作伙伴能夠利用其技術組合，涵蓋腫瘤學、免疫學和其他治療領域。</p>
<p>OmniAb 成立於 2016 年，總部位於華盛頓州西雅圖，於 2021 年 5 月上市。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票比 OmniAb 更好</li>
<li>你還認為白銀是個笑話嗎？看看接下來會發生什麼。</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>崩盤前一個月</li>
<li>埃隆將 SpaceX 上市！100 美元的首次公開募股機會！</li>
<li>YDES 可能是 2026 年的生物技術突破</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 OmniAb 嗎？</h2>
<p>在你考慮 OmniAb 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 OmniAb 並不在名單上。</p>
<p>雖然 OmniAb 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

OABI

<p>OmniAb (NASDAQ:OABI) 的股價上漲了 3.3%，達到 1.90 美元，交易量較平均水平下降了 52%。分析師維持 “適度買入” 的共識評級，目標價為 6.67 美元。公司報告的季度每股收益為（0.14 美元），超出預期，但收入為 224 萬美元，未達到預期。公司高管進行了減持，首席財務官和首席執行官都減少了持股。機構投資者持有 72.08% 的股份。OmniAb 專注於治療性抗體的開發，並於 2021 年 5 月上市</p>

<p>Shares of OmniAb, Inc. (NASDAQ:OABI - Get Free Report) traded up 3.3% during mid-day trading on Wednesday . The company traded as high as $1.9250 and last traded at $1.90. 264,447 shares traded hands during mid-day trading, a decline of 52% from the average session volume of 547,383 shares. The stock had previously closed at $1.84.</p>
<div class="lb-trans"><p>OmniAb, Inc.（NASDAQ:OABI - 獲取免費報告）的股票在週三的午盤交易中上漲了 3.3%。該公司的股票最高交易價格為 1.9250 美元，最後交易價格為 1.90 美元。在午盤交易中，共成交 264,447 股，較平均交易量 547,383 股下降了 52%。該股票此前收盤價為 1.84 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Separately, Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of OmniAb in a research report on Monday, December 22nd. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, OmniAb presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $6.67.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 12 月 22 日的研究報告中重申了對 OmniAb 股票的 “賣出（e+）” 評級。三位研究分析師給予該股票買入評級，一位分析師給予賣出評級。根據 MarketBeat.com 的數據，OmniAb 目前的共識評級為 “適度買入”，共識目標價為 6.67 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on OmniAb</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 OmniAb 的最新股票分析</strong></p>
</div><h2>OmniAb Stock Performance</h2>
<div class="lb-trans"><h2>OmniAb 股票表現</h2>
</div><p>The firm has a 50 day simple moving average of $1.80 and a two-hundred day simple moving average of $1.78. The stock has a market cap of $273.52 million, a P/E ratio of -3.28 and a beta of 0.13.</p>
<div class="lb-trans"><p>該公司的 50 日簡單移動平均線為 1.80 美元，200 日簡單移動平均線為 1.78 美元。該股票的市值為 2.7352 億美元，市盈率為-3.28，貝塔值為 0.13。</p>
</div><p>OmniAb (NASDAQ:OABI - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. OmniAb had a negative return on equity of 23.14% and a negative net margin of 301.83%.The company had revenue of $2.24 million during the quarter, compared to analysts' expectations of $5.64 million. As a group, equities research analysts predict that OmniAb, Inc. will post -0.61 EPS for the current year.</p>
<div class="lb-trans"><p>OmniAb（NASDAQ:OABI - 獲取免費報告）最近於 11 月 4 日發佈了季度財報。該公司報告每股收益（EPS）為-0.14 美元，超出市場共識預期的-0.15 美元，超出幅度為 0.01 美元。OmniAb 的股本回報率為-23.14%，淨利潤率為-301.83%。該公司在本季度的收入為 224 萬美元，而分析師預期為 564 萬美元。整體來看，股票研究分析師預測 OmniAb, Inc.在本年度將發佈-0.61 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at OmniAb</h2>
<div class="lb-trans"><h2>OmniAb 內部買賣情況</h2>
</div><p>In other OmniAb news, CFO Kurt A. Gustafson sold 23,922 shares of the firm's stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $1.96, for a total transaction of $46,887.12. Following the transaction, the chief financial officer owned 252,688 shares of the company's stock, valued at approximately $495,268.48. This trade represents a 8.65% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, CEO Matthew W. Foehr sold 13,666 shares of the business's stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $1.96, for a total transaction of $26,785.36. Following the sale, the chief executive officer owned 4,360,083 shares in the company, valued at $8,545,762.68. This trade represents a 0.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 45,632 shares of company stock valued at $89,439. Company insiders own 8.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他 OmniAb 新聞中，首席財務官 Kurt A. Gustafson 於 12 月 8 日星期一出售了 23,922 股該公司的股票。股票以平均價格 1.96 美元出售，總交易額為 46,887.12 美元。交易後，首席財務官持有該公司 252,688 股股票，價值約 495,268.48 美元。此交易代表其持股比例下降了 8.65%。該交易已在證券交易委員會的備案中披露，相關文件可通過此鏈接獲取。此外，首席執行官 Matthew W. Foehr 於 12 月 8 日星期一出售了 13,666 股該公司的股票。股票以平均價格 1.96 美元出售，總交易額為 26,785.36 美元。出售後，首席執行官持有該公司 4,360,083 股股票，價值 8,545,762.68 美元。此交易代表其持股比例下降了 0.31%。有關此銷售的更多細節可在官方 SEC 披露中找到。在過去 90 天內，內部人士已出售公司股票 45,632 股，價值 89,439 美元。公司內部人士持有公司股票的 8.60%。</p>
</div><h2>Institutional Investors Weigh In On OmniAb</h2>
<div class="lb-trans"><h2>機構投資者對 OmniAb 的看法</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio bought a new position in OmniAb during the second quarter valued at about $168,000. Connors Investor Services Inc. raised its position in OmniAb by 25.0% in the second quarter. Connors Investor Services Inc. now owns 62,000 shares of the company's stock worth $108,000 after acquiring an additional 12,389 shares in the last quarter. Towerview LLC lifted its holdings in OmniAb by 43.3% in the 2nd quarter. Towerview LLC now owns 831,100 shares of the company's stock valued at $1,446,000 after acquiring an additional 251,100 shares during the last quarter. Private Management Group Inc. boosted its position in shares of OmniAb by 1.1% during the 2nd quarter. Private Management Group Inc. now owns 2,558,045 shares of the company's stock valued at $4,451,000 after purchasing an additional 28,286 shares in the last quarter. Finally, Isthmus Partners LLC boosted its position in shares of OmniAb by 21.2% during the 2nd quarter. Isthmus Partners LLC now owns 568,043 shares of the company's stock valued at $988,000 after purchasing an additional 99,336 shares in the last quarter. 72.08% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些機構投資者最近增加或減少了對該公司的持股。俄亥俄州公共僱員退休系統在第二季度購買了 OmniAb 的新頭寸，價值約 168,000 美元。Connors Investor Services Inc.在第二季度將其在 OmniAb 的持股增加了 25.0%。Connors Investor Services Inc.目前持有 62,000 股該公司的股票，價值 108,000 美元，此前在上個季度又購買了 12,389 股。Towerview LLC 在第二季度將其在 OmniAb 的持股增加了 43.3%。Towerview LLC 目前持有 831,100 股該公司的股票，價值 1,446,000 美元，此前在上個季度又購買了 251,100 股。Private Management Group Inc.在第二季度將其在 OmniAb 的持股增加了 1.1%。Private Management Group Inc.目前持有 2,558,045 股該公司的股票，價值 4,451,000 美元，此前在上個季度又購買了 28,286 股。最後，Isthmus Partners LLC 在第二季度將其在 OmniAb 的持股增加了 21.2%。Isthmus Partners LLC 目前持有 568,043 股該公司的股票，價值 988,000 美元，此前在上個季度又購買了 99,336 股。目前 72.08% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>OmniAb Company Profile</h2>
<div class="lb-trans"><h2>OmniAb 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>OmniAb, Inc NASDAQ: OABI operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.</p>
<div class="lb-trans"><p>OmniAb, Inc. NASDAQ: OABI 是一家生物技術公司，專注於治療性抗體的發現和開發。該公司的綜合抗體發現平台結合了專有的轉基因動物模型、體外篩選和計算機工程，以加速候選藥物的識別和優化。OmniAb 提供按服務收費的合作和許可協議，使生物製藥合作伙伴能夠利用其技術組合，涵蓋腫瘤學、免疫學和其他治療領域。</p>
</div><p>Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.</p>
<div class="lb-trans"><p>OmniAb 成立於 2016 年，總部位於華盛頓州西雅圖，於 2021 年 5 月上市。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than OmniAb</li>
<li>You Still Think Silver’s a Joke? Watch What Happens Next.</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>A month before the crash</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>YDES Could Be 2026's Biotech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 OmniAb 更好</li>
<li>你還認為白銀是個笑話嗎？看看接下來會發生什麼。</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>崩盤前一個月</li>
<li>埃隆將 SpaceX 上市！100 美元的首次公開募股機會！</li>
<li>YDES 可能是 2026 年的生物技術突破</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in OmniAb Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 OmniAb 嗎？</h2>
</div><p>Before you consider OmniAb, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 OmniAb 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 OmniAb 並不在名單上。</p>
</div><p>While OmniAb currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 OmniAb 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

OmniAb（NASDAQ 代碼：OABI）股價上漲 3.3% - 接下來會如何發展？